The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.00
Bid: 2.00
Ask: 2.05
Change: -0.075 (-3.61%)
Spread: 0.05 (2.50%)
Open: 2.05
High: 2.09
Low: 2.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK MIDDAY BRIEFING: Royal Mail Up As It Meets Low Expectations

Thu, 22nd Jan 2015 12:00

LONDON (Alliance News) - Royal Mail is the best-performing stock on the FTSE 100 midday Thursday, after it put out trading figures for the first nine months of its financial year that met analysts' low expectations.

The mail and parcels operator said it is confident it will meet its own full-year expectations, after reporting that group revenue was up just 1% in the nine months to December 28, whilst revenue was flat in both its parcels and letters businesses.

The slight overall revenue growth marks a deterioration from the position half way through the mail operator's financial year, when revenue growth had stood at 2%. However, Royal Mail maintained its guidance that it'll keep most costs flat in the year as a whole, while volumes and revenue in its parcels business improved compared with the half year stage, and it continued to manage to offset the continued drop in letters volumes with price increases.

Still, Royal Mail said competition in the parcels sector remained tough, and several analysts said that will only hamper its prospects going forward.

Investec said it was retaining a Reduce rating on the stock due to the "considerable new parcel capacity coming into the market in the next 12 months". It said the most recent sales figures were broadly in line with expectations, although it said parcel pricing had been slightly below its own hopes.

Balfour Beatty's new chief executive has admitted he has a lot of work to do to turn around the business, after it cut expected 2014 profits from its UK construction business by a further GBP70 million following a review of the business, whilst raising its own valuation of its public-private partnership portfolio to GBP1.30 billion in the wake of a recent acquisition approach.

There could be a further UK construction hit to come, with Balfour warning that it would update the market on possible contract risk provisions in March.

In order to shore up its balance sheet, Balfour Beatty said it will cancel its proposed share buyback of up to GBP200 million and will also review its dividend policy in March when it puts out its full-year results.

Private equity firm KKR has bought thetrainline.com from owner Exponent for an undisclosed sum, diverting the online rail ticket platform from its planned London market listing.

Trainline had been set to list on the London Stock Exchange in an initial public offering that was set to raise about GBP75 million and value the company at about GBP500 million by market capitalisation.

Exponent is also the main selling shareholder of tool and equipment hire business HSS Hire Group, which on Thursday set the expected price range for its London Main Market IPO at between 210 pence to 262 pence per share. At the mid-point of the price range, HSS will have a market capitalisation of about GBP365 million on admission to the main market of the London Stock Exchange.

Imperial Tobacco Group and British American Tobacco are under pressure after UK Public Health Minister Jane Ellison said on Wednesday the government plans to vote on the introduction of standardised packaging for tobacco products before the General Election in May, with plans to implement the rules by May 2016.

----------
Markets: London's main market stock indices are higher, as investors await a long-anticipated move by the European Central Bank to add sovereign bond buying to its arsenal of stimulus measures. The euro is trading higher against the dollar ahead of the ECB monetary policy meeting scheduled for 1330 GMT.

US stocks are set for a marginally higher open, with stock futures indicating the DJIA and S&P 500 will open up 0.2% and the Nasdaq 100 up slightly.

FTSE 100: up 0.4% at 6,755.98
FTSE 250: up 0.5% at 16,329.18
AIM ALL-SHARE: down 0.1% at 699.49
GBP-USD: up at 1.5177
EUR-USD: up at USD1.1634
GOLD: down at USD1,286.70 an ounce
OIL (Brent): up at USD49.82 a barrel
----------
Top Corporate News
----------
St James's Place reported a 17% rise in funds under management to GBP52 billion in its last financial year, bolstered by strong new business figures and net inflows as it attracted more than 50,000 new clients. In a statement, the wealth management and financial advice group said that new business sales rose by 17% to GBP895.6 on an annual premium equivalent basis in 2014. In addition, third party new business, which arises from advice given on products and services of third party providers, rose to GBP598.1 million from GBP591.1 million.
----------
Tullow Oil announced a set of mixed results for its Kenyan prospects, with one well plugged and abandoned but seismic surveys showing improved prospects elsewhere. The company said the Epir-1 exploration well, located at Block 10BB in the North Kerio Basin, did not show an oil discovery, but had oil and wet gas shows over a 100 metre interval of non-reservoir quality rocks. Tullow said the results showed a working petroleum system in the basin and said further exploration activities will be considered for the North Kerio basin, but said the well itself would be plugged and abandoned, with the drilling rig to move to the Ekales-2 location in the South Lokichar basin. Elsewhere, Tullow has completed the survey on oil discoveries in the western South Lokichar basin. Tullow said initial evaluation of the 3D seismic data available has show significantly improved structural data and additional prospectivity which had not been available in the 2D seismic data.
----------
AstraZeneca said the European Medicines Agency has accepted its marketing authorisation application for gout treatment lesinurad 200 milligram tablets. Lesinurad is used for the chronic treatment of hyperuricaemia in combination with xanthine oxidase inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted, AstraZeneca said.
----------
Building materials business Wolseley said it has decided to explore exit options for its remaining building materials business in France, saying it was continuing to apply "disciplined resource allocation principles to all of its businesses".
----------
US media company Discovery Communications Inc has emerged as a potential challenger to BT Group and Sky for the upcoming Premier League football rights auction, the Financial Times reported. David Zaslav, Discovery's chief executive, travelled to London this week to hold talks with the Premier League, the FT said, citing people familiar with the matter. This year's auction is among the most anticipated ever held, with analysts expecting the value of the rights to increase by around 30% to GBP4 billion for the three years starting with the 2016-17 season.
----------
Smiths Group said it will pay US telecoms group AT&T Inc USD100 million to expand its global communication services infrastructure for the next six years.
----------
London-focused commercial property company CLS Holdings said it expects to beat the market for the full year. In a short trading statement, FTSE 250-listed CLS said it expects its financial results for the year to December 31 to be materially ahead of current market expectations on the back of a significant rise in the value of its London property portfolio.
----------
Countrywide said it expects to deliver record results for the year, though it reported a deterioration in market conditions over the course of 2014. Countrywide said it expects its revenue for the year to the end of December to be up 20%, with revenue rising 5% to GBP179.3 million in the fourth quarter.
----------
Playtech said it continued to trade well in the fourth quarter and expects to meet the market for the year. In a brief trading update, the FTSE 250-listed gaming software company said it expects revenue and adjusted earnings before income, taxation, depreciation and amortisation to be "comfortably" in line with market estimates.
----------
Oxford Instruments issued a profit warning as its orders were hit by Russian sanctions, it saw weaker trading in its Industrial Analysis business, and the recovery it had forecast for the Japanese market failed to occur. The technology tools and systems provider now expects to post a pretax profit adjusted for acquisition and related costs of around GBP35 million for the year to end-March, compared to an adjusted pretax profit of GBP47.1 million a year before.
----------
Paragon Group of Companies reported an 11% rise in first-quarter pretax profit, a performance it said was in line with its expectations, as the lender continues to benefit from strong UK buy-to-let lending. Paragon said that pretax profit, after a debit of about GBP700,000 for fair value hedging items, rose to GBP30.2 million in the final three months of 2014, from GBP27.1 million in the corresponding period last year. The group said its loan portfolios are performing well, generating strong profits and cash flows.
----------
Card Factory said it is trading in line with its expectations for the year on the back of a rise in revenue in the first eleven months as like-for-like sales rose despite strong comparables. Card Factory said for the 11 months to the end of December, revenue rose 8.1%. Like-for-like sales rose 1.8%, despite a strong comparable for last year when like-for-like sales increased 3.1%.
----------
AIM Movers
----------
Cyan Holdings shares are up by a quarter after it won an order worth about GBP1 million for a smart metering project in southwest India, which it believes is the first commercial implementation of smart metering by an Indian public utility. ImmuPharma is doing well after it signed a deal with Simbec-Orion Group Ltd to begin a phase III study of ImmuPharma's Lupuzor treatment for lupus and will get an investment from the company. 32Red is up after it said net gaming revenue rose by more than a quarter in 2014, marking a fifth consecutive year of double-digit growth, and said revenue growth had accelerated in the first few weeks of 2015. Evocutis is another gainer after it said there is "significant near and long term potential" to expand mining operations following the completion of a technical report compiled by Micon International Co Ltd and an operations update for the Bodó Tungsten Mine in Brazil. Stellar Diamonds is up after it raised GBP1 million in a share issue to back its Baoulé kimberlite project. TXO shares have fallen after its nominated adviser and broker Northland Capital Partners resigned. Northland's resignation will be effective from February 20. TXO said its shares will be suspended from trade on February 23 if a replacement adviser has not been appointed by that time. LPA Group is also down after it warned that its current financial year had got off to "an extremely slow start", meaning it's going to be playing catch-up for the rest of the year, although it added that its medium-term prospects remain bright. Monitise is another faller after it put itself up for sale, warning that it no longer expects to report double-digit revenue growth for the 2015 financial year, while its loss before interest, tax, depreciation and amortisation is also likely to widen from that reported in the prior year.
----------
Other Top Economics And General
----------
The UK's budget deficit increased in December from last year, the Office for National Statistics said. Public sector net borrowing excluding public sector banks totaled GBP 13.1 billion, an increase of GBP 2.9 billion or 27.8% from last year. The deficit was forecast to fall to GBP 9.7 billion. The increase was predominantly a result of an increase of GBP 2.5 billion in central government net borrowing.
----------
European Central Bank President Mario Draghi is set Thursday to launch an aggressive government bond-buying programme as part of the bank's efforts to spur economic growth and head off the threat of deflation in the eurozone. With the bank's refinancing rate at a historic low of 0.05%, Draghi has indicated that the bank does not have much more room to try to fire up the struggling 19-member currency bloc's economy though conventional monetary policy action. This leaves an unprecedented quantitative easing programme based on the purchases of government bonds - reportedly about EUR50 billion a month lasting for at least a year - as one of the bank's last options in its battle to haul the eurozone back from a bout of deflation that could derail the region's growth prospects for the coming years.
----------
The Bank of Japan assessed that the Japanese economy is recovering at a moderate pace, but inflation is likely to slow, the Monthly Report on Recent Economic and Financial Developments revealed. Japan's economy has continued to recover moderately as a trend as the effects of the decline in demand following the sales tax hike have been waning on the whole, it said. The year-on-year rate of increase in consumer prices is in the range of 0.5-1.0%, the bank noted. In the previous report, the bank had said that the growth in consumer prices was around 1%.
----------
The top US and EU diplomats vowed in Washington to support a unified sanctions regime against Russia and insisted Moscow abide by the Minsk ceasefire in eastern Ukraine. US Secretary of State John Kerry and the EU's new foreign policy chief, Federica Mogherini, spoke at a joint press conference in the Treaty Room at the State Department. Mogherini said the trip to Washington, her first trip in office outside the EU, was a sign of the significance of the close EU-US relationship.
----------
The speaker of the US House of Representatives, John Boehner, said he has invited Israeli Prime Minister Benjamin Netanyahu to speak next month to Congress. Boehner invited Netanyahu to speak on February 11 on the threats that radical Islam and Iran pose to Israeli and US security. The White House called Boehner's invitation a breach of normal diplomatic protocol.
----------
Afternoon Watchlist (all times in GMT)

All Day World Economic Forum - Davos
12:45 EU ECB Interest Rate Decision
13:30 EU ECB Monetary policy statement and press conference
13:30 US Jobless Claims
14:00 US Housing Price Index
15:00 EU Consumer Confidence Preliminary
15:30 US EIA Natural Gas Storage change
16:00 US EIA Crude Oil Stocks change
16:00 US Kansas Fed manufacturing activity
20:00 US American Petroleum Institute Monthly Report
----------
Friday's Key UK Corporate Events

Close Brothers Group - Trading Statement
Premier Foods - Q4 Interim Management Statement
---------
Friday's Key Economic Events (all times in GMT)

All Day World Economic Forum - Davos
01:35 Japan Nomura/ JMMA Manufacturing Purchasing Manager Index Preliminary
01:45 China HSBC Manufacturing PMI Preliminary
08:00 France Markit Manufacturing/Services PMI Preliminary
08:30 Germany Markit Manufacturing/Services PMI Preliminary
09:00 EU Markit Manufacturing/Services/Composite PMI Preliminary 5
09:00 Italy Trade Balance non-EU
09:30 UK Retail Sales
13:30 US Chicago Fed National Activity Index
14:45 US Markit Manufacturing PMI Preliminary
15:00 US CB Leading Indicator
15:00 US Existing Home Sales Change (MoM) -6.10%
15:00 US Existing Home Sales (MoM) 5.05M 4.93M
---------
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
2 Apr 2024 12:52

Immupharma jumps amid new IP strategy for P140 technology platform

(Alliance News) - Immupharma PLC on Tuesday announced a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform.

Read more
25 Mar 2024 12:20

Incanthera says first order from skincare deal doubles

(Alliance News) - ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in December 2023.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 10:55

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
6 Mar 2024 13:05

EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up

(Alliance News) - The following is a round-up of earnings and trading updates of London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
19 Dec 2023 17:52

EARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Dec 2023 12:18

IN BRIEF: Incanthera signs skincare stocking deal, raises GBP1 million

Incanthera PLC - develops technologies in dermatology and oncology - Raises GBP1.0 million in equity to support a deal that will see a major retailer stock Incanthera's 'Skin + Cell' range of skincare products. Raises GBP800,000 from the subscription to 11.4 million new shares at 7 pence each by new and existing institutional investors. At the same price, the University of Bradford converts GBP200,000 that is owed to it by Incanthera into 2.9 million new shares. The university, a founding shareholder in Incanthera, will own 11.2% of the enlarged share capital, with all the newly issued shares representing 15.5% of this. Incanthera also grants warrants to advisers to subscribe for another 800,000 new shares at the same price of 7p over the next 10 years. ImmuPharma PLC, which currently has a 12.7% stake in Incanthera, says it is "delighted" with the announcement of the skincare deal and successful fundraise.

Read more
7 Sep 2023 17:07

TRADING UPDATES: RA International loss narrows as revenue grows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
31 Aug 2023 13:05

ImmuPharma launches GBP2 million fund raise as interim loss narrows

(Alliance News) - ImmuPharma PLC on Thursday announced a share placing and a retail share offer to raise just under GBP2 million, while it also reported a narrowed loss in the first half of the year on reduced expenses.

Read more
21 Aug 2023 12:33

ImmuPharma agrees 12 month extension to Incanthera warrant instrument

(Alliance News) - Incanthera PLC and ImmuPharma PLC on Monday agreed a 12 month extension to their warrant instrument.

Read more
23 Jun 2023 15:51

UK shareholder meetings calendar - next 7 days

Monday 26 June 
Aterian PLCAGM
Capricorn Energy PLCAGM
Corre Energy BVAGM
Facilities by ADF PLCAGM
Lexington Gold LtdSGM re proposed acquisition of White Rivers Exploration Ltd
LifeSafe Holdings PLCAGM
Premier African Minerals LtdAGM
Vast Resources PLCGM re issuing new share capital
Volvere PLCAGM
Tuesday 27 June 
Acuity RM Group PLCAGM
Comptoir Group PLCAGM
Creo Medical Group PLCAGM
First Tin PLCAGM
Forward Partners Group PLCAGM
Galantas Gold CorpAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
Hamak Gold LtdAGM
ICG Enterprise Trust PLCAGM
Impellam Group PLCAGM
India Capital Growth Fund LtdAGM
Inspiration Healthcare Group PLCAGM
Instem PLCAGM
JD Sports Fashion PLCAGM
Kingfisher PLCAGM
Mercantile Ports & Logistics LtdGM re equity fundraising
Mobile Tornado Group PLCAGM
Revolution Beauty Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serabi Gold PLCAGM
Sondrel Holdings PLCAGM
Surface Transforms PLCAGM
Surgical Innovations Group PLCAGM
Trinity Exploration & Production PLCAGM
Wednesday 28 June 
Atalaya Mining PLCAGM
Avacta Group PLCAGM
Boku IncAGM
Cambridge Cognition Holdings PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Cobra Resources PLCAGM
Cora Gold LtdAGM
Dial Square Investments PLCAGM
Itaconix PLCAGM
NB Distressed Debt Investment Fund LtdAGM
Panthera Resources PLCGM re directors’ authority to allot shares
Phoenix Spree Deutschland LtdAGM
Pineapple Power Corp PLCAGM
Polarean Imaging PLCAGM
RA International Group PLCAGM
Schroder European Real Estate Investment Trust PLCAGM
Shield Therapeutics PLCAGM
St Mark Homes PLCAGM
Star Phoenix Group LtdAGM
ValiRx PLCAGM
Velocys PLCAGM
Vertu Motors PLCAGM
Warpaint London PLCAGM
Westminster Group PLCAGM
Zenova Group PLCAGM
Thursday 29 June 
3i Group PLCAGM
Africa Opportunity Fund LtdAGM
Anemoi International LtdAGM
Anpario PLCAGM
Ariana Resources PLCAGM
Beowulf Mining PLCAGM
Celadon Pharmaceuticals PLCAGM
Cornish Metals IncAGM
East Imperial PLCAGM
East Star Resources PLCAGM
Eden Research PLCAGM
Engage XR Holdings PLCAGM
First Class Metals PLCAGM
Gresham House Energy Storage Fund PLCGM re remuneration policy
Gusbourne PLCAGM
HeiQ PLCAGM
Helios Underwriting PLCAGM
Ingenta PLCAGM
IQE PLCAGM
Kooth PLCAGM
Landore Resources LtdAGM
Let's Explore Group PLCAGM
Likewise Group PLCAGM
MGC Pharmaceuticals LtdGM re issue of convertible notes
Morgan Advanced Materials PLCAGM
NetScientific PLCAGM
New Century AIM VCT 2AGM
Norman Broadbent PLCAGM
Reabold Resources PLCAGM
Rockhopper Exploration PLCAGM
Roquefort Therapeutics PLCAGM
Serica Energy PLCAGM
SpaceandPeople PLCAGM
Symphony Environmental Technologies PLCAGM
Synairgen PLCAGM
Thalassa Holdings LtdAGM
tinyBuild IncAGM
Touchstone Exploration IncAGM
Trident Royalties PLCAGM
Unigel Group PLCAGM
Verici Dx PLCAGM
Xpediator PLCAGM
Friday 30 June 
Argo Blockchain PLCAGM
Ascent Resources PLCAGM
Bluejay Mining PLCAGM
Caspian Sunrise PLCAGM
Codex Acquisitions PLCAGM
Domino's Pizza Group PLCGM re directors' remuneration policy
Fenikso LtdAGM
Fiinu PLCAGM
FireAngel Safety Technology Group PLCAGM
GENinCode PLCAGM
Hemogenyx Pharmaceuticals PLCAGM
Hiro Metaverse Acquisitions I SAAGM
i3 Energy PLCGM re premium share cancellation
ImmuPharma PLCAGM
Inspired PLCAGM
Jadestone Energy PLCAGM
Kanabo Group PLCAGM
Kefi Gold & Copper PLCAGM
Kistos Holdings PLCAGM
KRM22 PLCAGM
Kropz PLCAGM
LoopUp Group PLCAGM
Medica Group PLCAGM
Mirriad Advertising PLCAGM
Rockfire Resources PLCAGM
Savannah Energy PLCAGM
Strip Tinning Holdings PLCAGM
ThomasLloyd Energy Impact Trust PLCAGM
URA Holdings PLCAGM
World Chess PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
19 Jun 2023 12:02

IN BRIEF: ImmuPharma to start next two phases of Lupuzor trial

ImmuPharma PLC - London-based drug discovery and development company - Will start phases two and three of the clinical trial for Lupuzor in the seocnd half of 2023, following talks with the US Food & Drug Administration. Says the clinical trial will be supported by Avion Pharmaceuticals. Adds further details of the trial will be shared at a later stage. Lupuzor, or P140, is a potential treatment for Lupus disease.

Read more
18 May 2023 12:12

IN BRIEF: ImmuPharma rises on FDA feedback for neurological disease

ImmuPharma PLC - London-based drug discovery and development company - Gets positive support and guidance from the US Food & Drug Administration after a pre-investigational new drug meeting, which confirms the route for a Phase 2/3 adaptive clinical study of P140 in chronic idiopathic demyelinating polyneuropathy. Says the feedback recognises that P140 is suitable to be studied in another disease indication, in addition to systemic lupus erythematosus.

Read more
11 May 2023 11:48

IN BRIEF: ImmuPharma annual loss narrows as R&D spending reduced

ImmuPharma PLC - London-based drug discovery and development company - Posts no revenue for 2022, compared to GBP118,350 for 2021. Pretax loss narrows to GBP4.5 million from GBP8.9 million a year earlier, as operating loss reduces to GBP3.0 million from GBP6.6 million. Research and development expenditure is GBP2.0 million, down from GBP3.7 million in 2021. Chief Executive Officer Tim McCarthy says: "As a board, we remain focused on bringing our two key late stage clinical assets, Lupuzor for lupus and CIDP closer to the market."

Read more
19 Apr 2023 15:40

IN BRIEF: ImmuPharma says US FDA confirms date for Lupuzor meeting

ImmuPharma PLC - London-based drug discovery and development company - Notes the US Food & Drug Administration has set a date of June 7 for a type-C meeting to provide guidance on the phase 2/3 adaptive study of Lupuzor, or P140, in patients with systemic lupus erythematosus, a common type of immune disease lupus. Says this follows the announcement in late March, when it submitted a phase 2/3 clinical trial protocol to the US FDA testing the Lupuzor treatment for lupus patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.